Journal Articles Clinical Nutrition Year : 2017

Resting energy expenditure in the risk assessment of anticancer treatments

Abstract

Background & aims Alterations of nutritional and performance status (PS) are associated with higher risk of chemotherapy toxicity. Increased resting energy expenditure (REE) is frequent in cancer patients and may contribute to cachexia. We investigated whether abnormal energetic metabolism could predict early acute limiting toxicities (ELT) of anticancer treatments. Methods In this observational monocentric study, REE was measured by indirect calorimetry before treatment initiation. Based on the ratio of measured REE to REE predicted by the Harris–Benedict formula, patients were classified as hypometabolic (<90%), normometabolic (90–110%) or hypermetabolic (>110%). Body mass index, weight loss, PS, albumin, transthyretin, C-reactive protein (CRP) and muscle mass (CT-scan) were studied. Were defined as ELT any unplanned hospitalization or any adverse event leading to dose reduction or discontinuation during the first cycle of treatment. Results We enrolled 277 patients: 76% had metastatic disease; 89% received chemotherapy and 11% targeted therapy; 29% were normometabolic, 51% hypermetabolic and 20% hypometabolic. Fifty-nine patients (21%) experienced an ELT. Toxicity was associated with abnormal metabolism (vs normal: OR = 2.37 [1.13–4.94], p = 0.023), PS (2–3 vs 0–1: OR = 2.04 [1.12–3.74], p = 0.023), albumin (<35 vs ≥35 g/l: OR = 2.39 [1.03–5.54], p = 0.048), and inflammation (CRP ≥10 vs <10 mg/l: OR = 2.43 [1.35–4.38], p = 0.004). To predict toxicity, the most sensitive parameter was the REE (83%) followed by PINI (63%), GPS (59%), CRP (55%), PS (41%), NRI (37%), and albumin (16%). In multivariate analysis, elevated CRP was an independent predictor of toxicity (p = 0.047). Conclusion Abnormal basal energy metabolism identifies patients at higher risk of treatment-related acute complications.

Domains

Fichier principal
Vignette du fichier
REE_Jouinot_170103ChangesMade_AJ.pdf (297.66 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Licence

Dates and versions

hal-05410064 , version 1 (15-12-2025)

Licence

Identifiers

Cite

Anne Jouinot, Clara Vazeille, Jean Philippe Durand, Olivier Huillard, Pascaline Boudou-Rouquette, et al.. Resting energy expenditure in the risk assessment of anticancer treatments. Clinical Nutrition, 2017, 37 (2), pp.558-565. ⟨10.1016/j.clnu.2017.01.007⟩. ⟨hal-05410064⟩

Collections

44 View
86 Download

Altmetric

Share

  • More